NCT05188729Phase 2Completed

Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma

Study sponsor: Verrica Pharmaceuticals Inc. · VRCA

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-04-15Actual

Enrollment · participants92Actual

Source updated2025-06-18Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Basal Cell Carcinoma; Skin Cancer; Cancer of the Skin, Basal Cell; Cancer of the Skin; Carcinoma

Treatments or interventions studied

Part 1: VP-315 3 Day Dosing/WeekDrug
Part 2: VP-315 3 Day Dosing/Week - Loading DoseDrug
Part 2: VP-315 3 Day Dosing/Week - No Loading DoseDrug
Part 2: VP-315 2 Day Dosing/Week - Split DoseDrug
Part 2: VP-315 3 Day Dosing/Week - Split DoseDrug

Primary outcomes · main study measures

Read the study measures

measure: Part 1: Percentage of Subjects With Discontinuations Due to Adverse Events; description: Part 1: Percentage of subjects that discontinued the study due to adverse event; timeFrame: Up to 9 weeks; measure: Part 1: Percentage of Subjects With Dose-limiting Toxicities (DLTs); description: Subjects with pre-determined dose-limiting toxicities such as hypotension (specific criteria); significant elevation of serum tryptase; Grade 2 or higher adverse event (with specific criteria); timeFrame: Day 4 (Safety Assessment); measure: Part 1: Percentage of Subjects With Cutaneous Reaction by Maximum Severity; description: Cutaneous injection site reactions are defined as the following preferred terms: Injection site erythema, Injection site induration, Injection site swelling, Injection site vesicles, Injection site exfoliation, Injection site erosion, Injection site ulcer, Injection site necrosis. The intended scale for cutaneous injection site reactions is mild, moderate, severe from CRA. Subjects having more than one event may appear in more than one System Organ Class or Preferred Term but are counted at most once per each SOC and PT at the maximum severity. Cutaneous injection site reactions are types of reactions that can be expected to occur.; timeFrame: Up to 9 weeks; measure: Part 2: Percent of Subjects With Adverse Events; description: Part 2: Percent of subjects with adverse events, treatment-related AEs; timeFrame: Up to 15 weeks; measure: Part 2: Percentage of Subjects With Study Discontinuations Due to Adverse Events; description: Part 2: Percentage of subjects with study discontinuations due to adverse events.; timeFrame: Up to 15 weeks; measure: Part 2: Percent of Subjects With Treatment Related Adverse Events of Special Interest (TRAEs SI); description: Subjects with pre-determined TRAEs of SI such as hypotension (specific criteria); significant elevation of serum tryptase; Grade 2 or higher adverse event (with specific criteria); timeFrame: Treatment Days up to 2 weeks; measure: Part 2: Percentage of Subjects With Cutaneous Reaction by Maximum Severity; description: Evaluation of the tissue condition at the treatment site for the presence and severity of each of the following cutaneous reactions; Erythema, Induration, Swelling, Blister Formation, Desquamation, Erosion, Ulceration, Necrosis by a scale of None; Mild; Moderate; Severe. Subjects having more than one event may appear in more than one SOC or PT but are counted at most once per each SOC and PT at the maximum severity. Cutaneous injection site reactions are types of reactions that can be expected to occur. The intended scale for cutaneous injection site reactions is mild, moderate, severe from CRA; timeFrame: Up to 105 days

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history